<p><em>“可藥用靶點用於治療視網膜退化”</em></p>
<p><strong>佛羅里達州棕櫚灘花園，2026 年 1 月 23 日（環球新聞通訊社）--</strong> Curative Biotechnology, Inc.（OTC: CUBT）（“Curative” 或 “公司”），是一家開發基於二甲雙胍的眼藥水用於治療退行性眼病的公司，今天宣佈，加拿大知識產權局（CIPO）已對加拿大專利申請號 3,151,011 發出允許通知，標題為 <strong>“可藥用靶點用於治療視網膜退化。”</strong></p>
<p>Curative 是根據與國家眼科研究所（NEI）簽署的專利許可協議，全球獨家許可該技術。該發明是在 Dr. Kapil Bharti 及其團隊在 NEI 的領導下開發的，識別出一個與視網膜退行性疾病進展相關的新型藥理靶點。</p>
<p>“在加拿大的這一允許代表了我們建立全球知識產權組合以支持我們眼科平台的重要一步，” Curative Biotechnology 的董事長兼總裁 Paul Michaels 表示。</p>
<p>該加拿大專利包括 22 項已獲允許的權利要求，其中包括針對與基於二甲雙胍的配方相關的局部眼用給藥方法的權利要求，這與公司的預期給藥途徑相一致。該專利預計將在未來幾個月正式發佈。</p>
<p>公司之前已宣佈計劃將其基於二甲雙胍的眼藥水項目擴展到特定犬類（K9）視網膜退行性疾病的開發，這些疾病機制與人類視網膜退化觀察到的機制密切平行。這代表了一條平行的開發路徑，可能增強該平台的整體價值，同時滿足獸醫眼科的未滿足需求。</p>
<p>初步目標適應症包括：</p>
<ul>
<li><strong>進行性視網膜萎縮（PRA）</strong></li>
<li><strong>進行性杆錐細胞病（PRCD）</strong>，一種犬類罕見視網膜疾病</li>
</ul>
<p><strong>未來 Curative Biotechnology 新聞稿和更新</strong></p>
<p>感興趣的股東和投資者可以通過發送電子郵件至 ir@curativebiotech.com 請求未來新聞稿和公司更新的通知。</p>
<p><strong>關於 Curative Biotechnology, Inc.</strong></p>
<p>Curative Biotechnology, Inc.是一家處於開發階段的生物醫學公司，專注於識別和開發罕見疾病的新型治療方法。公司正在識別、收購和開發具有疾病修飾作用的治療藥物候選者，重點關注罕見疾病適應症。Curative 目前在退行性眼病、傳染病和神經腫瘤學領域維持項目。</p>
<p>公司的主要關注點是其退行性眼病平台，得到了來自國家眼科研究所（NEI）和國家衞生研究院（NIH）的全球獨家許可。其初步治療候選藥物是基於二甲雙胍的重新配方，旨在治療中期和晚期年齡相關性黃斑變性（AMD）。計劃於 2026 年進行首次人體臨牀試驗，具體取決於監管和運營準備情況，依據與 NEI 的合作研究與開發協議（CRADA）。</p>
<p><strong>前瞻性聲明</strong></p>
<p>本新聞稿包含根據 1933 年證券法第 27A 條和 1934 年證券交易法第 21E 條的定義的前瞻性聲明。前瞻性聲明包括但不限於關於專利發佈、開發策略、臨牀時間表和潛在治療應用的聲明。這些聲明基於當前的預期和假設，並受到可能導致實際結果顯著不同的風險和不確定性的影響。</p>
<p>這些風險包括但不限於與知識產權保護、監管批准、臨牀開發、資本獲取、對第三方合作伙伴的依賴、市場接受度以及公司執行其商業戰略能力相關的不確定性。</p>
<p>鼓勵讀者查看公司在 OTC 市場提交的披露，以獲得更全面的風險因素討論。除法律要求外，公司沒有義務更新前瞻性聲明。</p>
<p><strong>聯繫方式：</strong></p>
<p><strong>Paul Michaels</strong></p>
<p>執行董事長</p>
<p>直接電話：917-492-8855</p>
<p><strong>投資者關係</strong></p>
<p>Curative Biotechnology, Inc. (CUBT)</p>
<p>ir@curativebiotech.com</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RZek1UUTROaU0zTXpjNE1EQTBJelV3TURBM01Ea3lOdz09?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="1" height="1" original-src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RZek1UUTROaU0zTXpjNE1EQTBJelV3TURBM01Ea3lOdz09"/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/YjI4ZjAwYjQtNTNhZS00NDMzLThkYWMtNmZlNmJmOWZiY2Y2LTUwMDA3MDkyNy0yMDI2LTAxLTIzLWVu/tiny/Curative-Biotechnology-Inc-.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="1" height="1" original-src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/YjI4ZjAwYjQtNTNhZS00NDMzLThkYWMtNmZlNmJmOWZiY2Y2LTUwMDA3MDkyNy0yMDI2LTAxLTIzLWVu/tiny/Curative-Biotechnology-Inc-.png"/></p>

CUBT

CUBTD

<p>Curative Biotechnology, Inc. 宣佈，加拿大知識產權局已發出其與治療視網膜退化相關的新型藥理靶點的專利申請的允許通知。該專利支持公司基於二甲雙胍的眼藥水項目，旨在解決人類和犬類的退行性眼病。該專利包括 22 項允許的權利要求，預計將很快正式頒發。Curative 專注於開發罕見疾病的治療方法，並計劃在 2026 年進行其年齡相關性黃斑變性（AMD）治療的臨牀試驗</p>

<p><em>“Druggable Target to Treat Retinal Degeneration”</em></p>
<div class="lb-trans"><p><em>“可藥用靶點用於治療視網膜退化”</em></p>
</div><p><strong>Palm Beach Gardens, FL, Jan. 23, 2026 (GLOBE NEWSWIRE) --</strong> Curative Biotechnology, Inc. (OTC: CUBT) (“Curative” or the “Company”), a company developing metformin-based eye drops for the treatment of degenerative eye diseases, today announced that the Canadian Intellectual Property Office (CIPO) has issued a Notice of Allowance for Canadian Patent Application No. 3,151,011, entitled <strong>“Druggable Target to Treat Retinal Degeneration.”</strong></p>
<div class="lb-trans"><p><strong>佛羅里達州棕櫚灘花園，2026 年 1 月 23 日（環球新聞通訊社）--</strong> Curative Biotechnology, Inc.（OTC: CUBT）（“Curative” 或 “公司”），是一家開發基於二甲雙胍的眼藥水用於治療退行性眼病的公司，今天宣佈，加拿大知識產權局（CIPO）已對加拿大專利申請號 3,151,011 發出允許通知，標題為 <strong>“可藥用靶點用於治療視網膜退化。”</strong></p>
</div><p>Curative is the exclusive worldwide licensee of this technology pursuant to a patent license agreement with the National Eye Institute (NEI), part of the National Institutes of Health (NIH). The invention, developed under the leadership of Dr. Kapil Bharti and his team at the NEI, identifies a novel pharmacological target with potential relevance to the progression of retinal degenerative diseases.</p>
<div class="lb-trans"><p>Curative 是根據與國家眼科研究所（NEI）簽署的專利許可協議，全球獨家許可該技術。該發明是在 Dr. Kapil Bharti 及其團隊在 NEI 的領導下開發的，識別出一個與視網膜退行性疾病進展相關的新型藥理靶點。</p>
</div><p>“This allowance in Canada represents an important step in our strategy to build a global intellectual property portfolio supporting our ophthalmology platform,” said Paul Michaels, Chairman and President of Curative Biotechnology.</p>
<div class="lb-trans"><p>“在加拿大的這一允許代表了我們建立全球知識產權組合以支持我們眼科平台的重要一步，” Curative Biotechnology 的董事長兼總裁 Paul Michaels 表示。</p>
</div><p>The Canadian patent includes 22 allowed claims, including claims directed toward topical ocular delivery approaches relevant to metformin-based formulations, which align with the Company’s intended route of administration. The patent is expected to formally issue in the coming months.</p>
<div class="lb-trans"><p>該加拿大專利包括 22 項已獲允許的權利要求，其中包括針對與基於二甲雙胍的配方相關的局部眼用給藥方法的權利要求，這與公司的預期給藥途徑相一致。該專利預計將在未來幾個月正式發佈。</p>
</div><p>The Company has previously announced plans to expand development of its metformin-based eye drop program into select canine (K9) retinal degenerative indications, where disease mechanisms closely parallel those observed in human retinal degeneration. This represents a parallel development pathway that may enhance the overall value of the platform while addressing unmet needs in veterinary ophthalmology.</p>
<div class="lb-trans"><p>公司之前已宣佈計劃將其基於二甲雙胍的眼藥水項目擴展到特定犬類（K9）視網膜退行性疾病的開發，這些疾病機制與人類視網膜退化觀察到的機制密切平行。這代表了一條平行的開發路徑，可能增強該平台的整體價值，同時滿足獸醫眼科的未滿足需求。</p>
</div><p>Initial target indications include:</p>
<div class="lb-trans"><p>初步目標適應症包括：</p>
</div><ul>
<li><strong>Progressive Retinal Atrophy (PRA)</strong></li>
<li><strong>Progressive Rod and Cone Disease (PRCD</strong>), a rare retinal disease in canines</li>
</ul>
<div class="lb-trans"><ul>
<li><strong>進行性視網膜萎縮（PRA）</strong></li>
<li><strong>進行性杆錐細胞病（PRCD）</strong>，一種犬類罕見視網膜疾病</li>
</ul>
</div><p><strong>Future Curative Biotechnology Press Releases and Updates</strong></p>
<div class="lb-trans"><p><strong>未來 Curative Biotechnology 新聞稿和更新</strong></p>
</div><p>Interested shareholders and investors may request notification of future press releases and corporate updates by emailing ir@curativebiotech.com.</p>
<div class="lb-trans"><p>感興趣的股東和投資者可以通過發送電子郵件至 ir@curativebiotech.com 請求未來新聞稿和公司更新的通知。</p>
</div><p><strong>About Curative Biotechnology, Inc.</strong></p>
<div class="lb-trans"><p><strong>關於 Curative Biotechnology, Inc.</strong></p>
</div><p>Curative Biotechnology, Inc. is a development-stage biomedical company focused on the identification and development of novel therapeutic approaches for rare diseases. The Company is identifying, acquiring, and developing disease-modifying therapeutic drug candidates with an emphasis on rare disease indications. Curative currently maintains programs in degenerative eye disease, infectious disease, and neuro-oncology.</p>
<div class="lb-trans"><p>Curative Biotechnology, Inc.是一家處於開發階段的生物醫學公司，專注於識別和開發罕見疾病的新型治療方法。公司正在識別、收購和開發具有疾病修飾作用的治療藥物候選者，重點關注罕見疾病適應症。Curative 目前在退行性眼病、傳染病和神經腫瘤學領域維持項目。</p>
</div><p>The Company’s primary focus is its degenerative eye disease platform, supported by a worldwide exclusive license from the National Eye Institute (NEI) at the National Institutes of Health (NIH). Its initial therapeutic candidate is a metformin-based reformulation intended for the treatment of intermediate and late-stage Age-Related Macular Degeneration (AMD). A first-in-human clinical trial is planned for 2026, subject to regulatory and operational readiness, under a Cooperative Research and Development Agreement (CRADA) with the NEI.</p>
<div class="lb-trans"><p>公司的主要關注點是其退行性眼病平台，得到了來自國家眼科研究所（NEI）和國家衞生研究院（NIH）的全球獨家許可。其初步治療候選藥物是基於二甲雙胍的重新配方，旨在治療中期和晚期年齡相關性黃斑變性（AMD）。計劃於 2026 年進行首次人體臨牀試驗，具體取決於監管和運營準備情況，依據與 NEI 的合作研究與開發協議（CRADA）。</p>
</div><p><strong>Forward-Looking Statements</strong></p>
<div class="lb-trans"><p><strong>前瞻性聲明</strong></p>
</div><p>This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements include, but are not limited to, statements regarding patent issuance, development strategies, clinical timelines, and potential therapeutic applications. These statements are based on current expectations and assumptions and are subject to risks and uncertainties that could cause actual results to differ materially.</p>
<div class="lb-trans"><p>本新聞稿包含根據 1933 年證券法第 27A 條和 1934 年證券交易法第 21E 條的定義的前瞻性聲明。前瞻性聲明包括但不限於關於專利發佈、開發策略、臨牀時間表和潛在治療應用的聲明。這些聲明基於當前的預期和假設，並受到可能導致實際結果顯著不同的風險和不確定性的影響。</p>
</div><p>Such risks include, among others, uncertainties related to intellectual property protection, regulatory approvals, clinical development, access to capital, reliance on third-party collaborators, market acceptance, and the Company’s ability to execute its business strategy.</p>
<div class="lb-trans"><p>這些風險包括但不限於與知識產權保護、監管批准、臨牀開發、資本獲取、對第三方合作伙伴的依賴、市場接受度以及公司執行其商業戰略能力相關的不確定性。</p>
</div><p>Readers are encouraged to review the Company’s disclosures filed with OTC Markets for a more complete discussion of risk factors. The Company undertakes no obligation to update forward-looking statements, except as required by law.</p>
<div class="lb-trans"><p>鼓勵讀者查看公司在 OTC 市場提交的披露，以獲得更全面的風險因素討論。除法律要求外，公司沒有義務更新前瞻性聲明。</p>
</div><p><strong>Contact:</strong></p>
<div class="lb-trans"><p><strong>聯繫方式：</strong></p>
</div><p><strong>Paul Michaels</strong></p>
<div class="lb-trans"><p><strong>Paul Michaels</strong></p>
</div><p>Executive Chairman</p>
<div class="lb-trans"><p>執行董事長</p>
</div><p>Direct: 917-492-8855</p>
<div class="lb-trans"><p>直接電話：917-492-8855</p>
</div><p><strong>Investor Relations</strong></p>
<div class="lb-trans"><p><strong>投資者關係</strong></p>
</div><p>Curative Biotechnology, Inc. (CUBT)</p>
<div class="lb-trans"><p>Curative Biotechnology, Inc. (CUBT)</p>
</div><p>ir@curativebiotech.com</p>
<div class="lb-trans"><p>ir@curativebiotech.com</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RZek1UUTROaU0zTXpjNE1EQTBJelV3TURBM01Ea3lOdz09" alt="" original-src="https://www.globenewswire.com/newsroom/ti?nf=OTYzMTQ4NiM3Mzc4MDA0IzUwMDA3MDkyNw=="/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/YjI4ZjAwYjQtNTNhZS00NDMzLThkYWMtNmZlNmJmOWZiY2Y2LTUwMDA3MDkyNy0yMDI2LTAxLTIzLWVu/tiny/Curative-Biotechnology-Inc-.png" alt="" original-src="https://ml.globenewswire.com/media/YjI4ZjAwYjQtNTNhZS00NDMzLThkYWMtNmZlNmJmOWZiY2Y2LTUwMDA3MDkyNy0yMDI2LTAxLTIzLWVu/tiny/Curative-Biotechnology-Inc-.png"/></p>

Curative Biotechnology 宣佈獲得加拿大專利許可 | CUBT 股票新聞